Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Rhein Biotech's vaccines strategy

Rhein Biotech N.V. has abandoned its blue-collar roots in enabling technology to become a more up-scale vaccine products company. Rhein (NMarkt:RBO, Maastricht, the Netherlands) had been producing and outlicensing recombinant proteins until last week, when it acquired

Read the full 377 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers